TCC, Human, Monoclonal Antibody aE11, FITC
- Supplier: Hycult Biotech
Product Description
- Monoclonal antibody aE11 reacts with a C9 neoantigen of the terminal complement complex (TCC). The three distinct activation pathways of complement converge with the formation of a C5 convertase. The cleavage of C5 by this convertase initiates the lytic or terminal pathway. In contrast to the activation pathways, which require enzymatic cleavage for activation, the terminal pathway relies on conformational changes induced by binding. Binding of C6 facilitates binding of C7 which alters the conformation of the complex. After binding of C8, a variable number of C9 molecules associate with the C5b678 complex, which is also termed- the terminal complement complex (TCC). The formation of TCC causes lysis of cells or can trigger a variety of cellular metabolic pathways resulting in the synthesis and release of inflammatory mediators. The TCC contains neoantigens that are absent from the individual native components.- C9 neoantigens are present both in the membrane-bound (MAC) and the fluid-phase (SC5b-9) complex. TCC is present in normal human plasma and increased in patients with complement activation.
- Applications: Frozen sections, Flow Cytometry , Functional Studies , Immunoassays , Immunofluorescence , Paraffin Sections
Resources
Product Options
| Product Number | Description | Package Size | List Price (CAD) | ||
|---|---|---|---|---|---|
| HYBHM2167F20UG | TCC, Human, mAb aE11, FITC, 20 µg | 20 µg |
CA$242.30
|
Add to Cart | |
| HYBHM2167F100UG | TCC, Human, mAb aE11, FITC, 100 µg | 100 µg |
CA$930.00
|
Add to Cart |
List Prices are displayed.
Please register or log-in to the site to view your organization’s prices, or please add the products to your cart and click the “Request a Quote” button to receive price and availability information (include quantities for each product and indicate either a one-time purchase or your annual usage.)